Assembled
Senior Team
Secured Support From Italy & Canada
Endorsement
By EMA
Virna Therapeutics is focused to develop neutralizing monoclonal antibody (mAb) that should prevent the SARS-CoV-2 from entering human host cells to combat the COVID-19, and also its other strains that could emerge as threats in the future.
Virna Therapeutics has brought a multi-national team from USA, Canada, Italy and India to rapidly develop the therapeutic antibodies. The funding by Canadian Govt has been pivotal for discovery work thus far, and ministry of health has extended a full support for rapid development. Government of Italy has extended a full support for manufacturing and clinical development of the antibodies.
Virna has identified an Indian Industry partner, Intonation Research Laboratories, Pvt. Ltd. Hyderabad, for an exclusive development and marketing right for South East Asia. The plan for India is to help in characterizing antibody, parallel scale up and clinical trials.
Prof. at University of Toronto and founder of the Toronto Recombinant Antibody Centre (TRAC) for Commercialization of Antibodies and Biologics.
Prof. at Beth Israel Deaconess Medical Center, Harvard Medical School and a preeminent molecular geneticist and cancer biologist.
A successful biotech entrepreneur with an impressive track record of building effective organizations. Founder and former COO and CSO of Acylin Therapeutics.
An experienced drug discovery scientist and advanced several discovery programs to IND. He
was President for a bio-therapeutic CRO in USA. His can be contacted at
jgupta@intotech.net
(phone 9866560310)
Section Head, Mammalian Cell Expression National Research Council of Canada
M.D. , FRCPC , Ph.D. Advisor Clinical Affairs Director, Oral Immunotherapy Clinic (CITO), CHU Sainte-Justine Leader CPT - Canadian national effort
PhD Advisor, R&D Professor, Med Genetics Tor Vergata Univ of Rome Director, U.O.C. Medical Genetics
© 2020 Virna Therapeutics.All rights reserved.